Holen Sie sich die Stockscreener-App
10.29
3.02%
-0.32
Handel nachbörslich:
10.29
Schlusskurs vom Vortag:
$10.61
Offen:
$10.61
24-Stunden-Volumen:
233.32K
Relative Volume:
0.72
Marktkapitalisierung:
$546.30M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-83.74M
KGV:
-6.3913
EPS:
-1.61
Netto-Cashflow:
$-64.98M
1W Leistung:
+1.58%
1M Leistung:
+11.48%
6M Leistung:
-34.87%
1J Leistung:
-50.48%
1-Tages-Spanne:
$10.08
$11.09
1-Wochen-Bereich:
$10.08
$11.31
52-Wochen-Spanne:
$6.42
$29.60
Tyra Biosciences Inc Stock (TYRA) Company Profile
Firmenname
Tyra Biosciences Inc
Sektor
Branche
Telefon
(619) 728-4760
Adresse
2656 STATE STREET, CARLSBAD
Vergleichen Sie TYRA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TYRA
Tyra Biosciences Inc
|
10.29 | 538.69M | 0 | -83.74M | -64.98M | -1.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Tyra Biosciences Inc Stock (TYRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-21 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-01-07 | Eingeleitet | UBS | Buy |
| 2024-10-18 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-08-15 | Eingeleitet | Piper Sandler | Overweight |
| 2023-12-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-06-30 | Eingeleitet | Wedbush | Outperform |
| 2023-02-03 | Eingeleitet | Oppenheimer | Outperform |
| 2022-06-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-03-08 | Hochstufung | Jefferies | Hold → Buy |
| 2021-11-08 | Herabstufung | Jefferies | Buy → Hold |
| 2021-10-11 | Eingeleitet | BofA Securities | Buy |
| 2021-10-11 | Eingeleitet | Cowen | Outperform |
| 2021-10-11 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Tyra Biosciences Inc Aktie (TYRA) Neueste Nachrichten
What drives Tyra Biosciences Inc. stock priceRapid wealth creation - Autocar Professional
Is Tyra Biosciences Inc. a good long term investmentSuperior returns - jammulinksnews.com
Why Tyra Biosciences Inc. stock attracts strong analyst attentionHigh Yield Opportunities - Newser
What analysts say about Tyra Biosciences Inc. stockConsistently high returns - jammulinksnews.com
Tyra Biosciences Inc. Stock Analysis and ForecastSkyrocketing profit margins - Autocar Professional
Achondroplasia Breakthrough? Tyra Biosciences CEO Reveals Latest Treatment Progress at UBS Fireside Chat - Stock Titan
June Brings on Some Huge Insider Buying - AOL.com
What analysts say about HOOK stockPhenomenal capital appreciation - jammulinksnews.com
Trading (TYRA) With Integrated Risk Controls - news.stocktradersdaily.com
What drives Diana Shipping Inc. stock priceSuperior profit margins - Jammu Links News
What drives Third Harmonic Bio Inc. stock priceOutstanding risk-reward balance - jammulinksnews.com
Tyra Biosciences Rises On Precision Medicine Hopes And Analyst Support - Finimize
What makes Tyra Biosciences Inc. stock price move sharplySmart Return Focused Trading - Newser
How Tyra Biosciences Inc. stock performs during market volatilityInsider Strategy Insight - Newser
Tyra Biosciences Insider Lowered Holding By 58% During Last Year - simplywall.st
Advanced Urothelial Carcinoma Clinical Trials 2025: EMA, PDMA, - openPR.com
Oppenheimer Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $30 - 富途牛牛
Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025 - Eastern Progress
Tyra Biosciences' TYRA-300 Emerges as Dual-Threat Therapy, Poised to Drive Clinical and Market Momentum - AInvest
New TYRA-300 Preclinical Data Reveals Promising Results for Rare Bone Growth Disorder Treatment - Stock Titan
Where are the Opportunities in (TYRA) - news.stocktradersdaily.com
Tyra Biosciences’ (TYRA) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
TYRA-300 Begins Phase 2 Trial in FGFR3-Altered NMIBC - Targeted Oncology
Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302) - Longview News-Journal
Tyra Biosciences, Inc.(NasdaqGS: TYRA) added to Russell 2000 Value Index - MarketScreener
Tyra Bioscience Launches Phase 2 Study for TYRA-300 - TipRanks
When the Price of (TYRA) Talks, People Listen - news.stocktradersdaily.com
Non-Muscle Invasive Bladder Cancer Market Set to Grow Substantially Through 2034, DelveInsight Projects | CG Oncology, Pfizer, UroGen Pharma, Janssen Research & Development, LLC, Protara Therapeutics - The Globe and Mail
California State Teachers Retirement System Sells 2,366 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 10,426 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) - Defense World
Finanzdaten der Tyra Biosciences Inc-Aktie (TYRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):